Approaching a decades-old goal: Making blood stem cells from patients' own cells

Researchers at Boston Children's Hospital have, for the first time, generated blood-forming stem cells in the lab using pluripotent stem cells, which can make virtually every cell type in the body. The advance, published today in the journal Nature, opens new avenues for research into the root causes of blood diseases and to creating immune-matched blood cells for treatment purposes, derived from patients' own cells.

"We're tantalizingly close to generating bona fide human blood stem cells in a dish," says senior investigator George Daley, MD, PhD, who heads a research lab in Boston Children's Hospital's Stem Cell Program and is dean of Harvard Medical School. "This work is the culmination of over 20 years of striving."

Although the cells made from the pluripotent stem cells are a mix of true blood stem cells and other cells known as blood progenitor cells, they proved capable of generating multiple types of human blood cells when put into mice.

"This step opens up an opportunity to take cells from patients with genetic blood disorders, use gene editing to correct their genetic defect and make functional blood cells," says Ryohichi (Rio) Sugimura, MD, PhD, the study's first author and a postdoctoral fellow in the Daley Lab. "This also gives us the potential to have a limitless supply of blood stem cells and blood by taking cells from universal donors. This could potentially augment the blood supply for patients who need transfusions."

Combining two approaches to achieve a breakthrough

Since human embryonic stem (ES) cells were isolated in 1998, scientists have been trying, with little success, to use them to make blood-forming stem cells. In 2007, three groups (including the Daley lab) generated the first induced pluripotent stem (iPS) cells from human skin cells through genetic reprogramming. iPS cells were later used to generate multiple human cell types, such as neurons and heart cells -- yet blood-forming stem cells remained elusive.

Sugimura, Daley and colleagues combined two previous approaches. First, they exposed human pluripotent stem cells (both ES and iPS cells) to chemical signals that direct stem cells to differentiate into specialized cells and tissues during normal embryonic development. This generated hemogenic endothelium, an early embryonic tissue that eventually gives rise to blood stem cells, although the transition to blood stem cells had never been achieved in a dish.

In the second step, the team added genetic regulatory factors (called transcription factors) to push the hemogenic endothelium toward a blood-forming state. Starting with 26 transcription factors identified as likely candidates, they eventually came down to just five (RUNX1, ERG, LCOR, HOXA5 and HOXA9) that were both necessary and sufficient for creating blood stem cells. They delivered the factors into the cells with a lentivirus, as used in some forms of gene therapy.

Finally, they transplanted the genetically engineered hemogenic endothelial cells into mice. Weeks later, a small number of the animals carried multiple types of human blood cells in their bone marrow and blood circulation. These included red blood cell precursors, myeloid cells (precursors of monocytes, macrophages, neutrophils, platelets and other cells), and T and B lymphocytes. Some mice were able to mount a human immune response after vaccination.

ES cells and iPS cells were similarly good at creating blood stem and progenitor cells when the technique was applied. But the researchers are most interested in iPS cells, which offer the added ability to derive cells directly from patients and model disease.

"We're now able to model human blood function in so-called 'humanized mice,'" says Daley. "This is a major step forward for our ability to investigate genetic blood disease."

What is a blood stem cell?

The researchers' technique produced a mixture of blood stem cells and so-called hematopoietic progenitor cells, which also give rise to blood cells. Their ultimate goal is to expand their ability to make true blood stem cells in a way that's practical and safe, without the need for viruses to deliver the transcription factors, and to introduce gene-editing techniques like CRISPR to correct genetic defects in pluripotent stem cells before blood cells are made.

One challenge in making bona-fide human blood stem cells is that no one's been able to fully characterize these cells.

"It's proved challenging to 'see' these cells," says Sugimura. "You can roughly characterize blood stem cells based on surface markers, but even with this, it may not be a true blood stem cell. And once it starts to differentiate and make blood cells, you can't go back and study it -- it's already gone. A better characterization of human blood stem cells and a better understanding of how they develop would give us clues to making bona-fide human blood stem cells."

-end-

The study was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (R24DK092760), the National Institute of Allergy and Infectious Diseases (R37AI039394), the National Heart, Lung, Blood Institute Progenitor Cell Biology Consortium (UO1-HL100001), Alex's Lemonade Stand, the Doris Duke Medical Foundation, the American Society of Hematology Scholar Fellowship and the Howard Hughes Medical Institute.

Boston Children's Hospital is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 1,100 scientists, including seven members of the National Academy of Sciences, 11 members of the Institute of Medicine and 10 members of the Howard Hughes Medical Institute comprise Boston Children's research community. Founded as a 20-bed hospital for children, Boston Children's today is a 415-bed comprehensive center for pediatric and adolescent health care. Boston Children's is also the primary pediatric teaching affiliate of Harvard Medical School. For more, visit our Vector and Thriving blogs and follow us on our social media channels: @BostonChildrens, @BCH_Innovation, Facebook and YouTube.

Almost daily, new technologies are being presented that move the field of human pluripotent stem cell research towards a future that may yield highly-effective, personalized medical treatments. Three enabling technologies at hand for human PSCs are 1) directed reprogramming of somatic cells, which eliminate many of the ethical issues associated with the derivation and use of human PSCs, increase genetic diversity of the available human PSC lines, and give rise to better in vitro human disease models; 2) the discovery that a Rho-associated protein Kinase (ROCK) inhibitor allows for... View Details

This volume looks at the state-of-the-science in stem cells, discusses the current challenges, and examines the new directions the field is taking. Dr. Turksen, editor-in-chief of the journal "Stem Cell Reviews and Reports," has assembled a volume of internationally-known scientists who cover topics that are both clinically and research-oriented. The contents range from sources of stem cells through their physiological role in health and disease, therapeutic applications in regenerative medicine, and ethics and society. An initial overview and a final summary bookend the contents into a... View Details

This volume captures the rapid developments in the field of induced pluripotent stem (iPS) cells, which have provided novel opportunities and approaches both for better understanding a number of human diseases and for developing new platforms for drug development and screening for such diseases. Specifically, representative protocols on various disease models have been collected from labs around the world. Written for the highly successful Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents,... View Details

Stem Cells and Tissue Repair: Methods and Protocols presents in-depth methods for the three major approaches of rejuvenating an aging or sick body: latent regenerative capacity stimulated in a targeted way, replacement organs grown de novo and surgically implanted, and tissue surgically implanted and coaxed to integrate and restore problem areas. The first approach taps into the latent regenerative capacity of particular tissues, such as muscle, skin, fat, or bone marrow. The second approach induces and grows pluripotent stem cells, drives their differentiation along certain... View Details

Introduces all of the essential cell biology and developmental biology background for the study of stem cells

This book gives you all the important information you need to become a stem cell scientist. It covers the characterization of cells, genetic techniques for modifying cells and organisms, tissue culture technology, transplantation immunology, properties of pluripotent and tissue specific stem cells and, in particular, the relevant aspects of mammalian developmental biology. It dispels many misconceptions about stem cells—especially that they can be miracle... View Details

Fully revised for the fifth edition, this outstanding reference on bone marrow transplantation is an essential, field-leading resource. Extensive coverage of the field, from the scientific basis for stem-cell transplantation to the future direction of research Combines the knowledge and expertise of over 170 international specialists across 106 chapters Includes new chapters addressing basic science experiments in stem-cell biology, immunology, and tolerance Contains expanded content on the benefits and challenges of transplantation, and analysis of the impact of new therapies to help... View Details

Engineering Neural Tissue from Stem Cells covers the basic knowledge needed to understand the nervous system and how existing cells can be used to create neural tissue. This book presents a broad range of topics related to the design requirements for engineering neural tissue from stem cells. It begins with the anatomy and function of the central and peripheral nervous system, also covering stem cells, their relation to the nervous system and their function in recovery after injury or disease. In addition, the book explores the role of the extracellular matrix and vasculature/immune... View Details

This volume aims to be a collection of essential protocols in iPS cell field. Induced Pluripotent Stem (iPS) Cells: Methods and Protocolsguides readers through multiple facets of stem cell biology, lineage commitment and differentiation. Written for the Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.

The 4th annual “Induced pluripotent stem cells” meeting, organized by EuroSciCon, was part of the 2013 Stem Cell Trilogy Event. The main topics of the conference included: human iPS cells with emphasis on the clinical applications, tissue engineering and regenerative medicine.

The first session of the meeting was chaired by Dr. Lyn Healy, who has more than 20 years of experience in the stem cell field and holds a position as senior Stem Cell Biologist at the UK Stem Cell Bank (National Institute for Biological Standards and Control, UK). An interesting aspect of the sessions... View Details

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.

#465 How The Nose KnowsWe've all got a nose but how does it work? Why do we like some smells and not others, and why can we all agree that some smells are good and some smells are bad, while others are dependant on personal or cultural preferences? We speak with Asifa Majid, Professor of Language, Communication and Cultural Cognition at Radboud University, about the intersection of culture, language, and smell. And we level up on our olfactory neuroscience with University of Pennsylvania Professor Jay Gottfried.